- Home
- ACAD vs CSAN Comparison
ACAD vs CSAN Comparison
Compare ACAD & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- CSAN
- Stock Information
- Founded
- ACAD 1993
- CSAN 1936
- Country
- ACAD United States
- CSAN Brazil
- Employees
- ACAD N/A
- CSAN N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- CSAN Retail-Auto Dealers and Gas Stations
- Sector
- ACAD Health Care
- CSAN Consumer Discretionary
- Exchange
- ACAD Nasdaq
- CSAN Nasdaq
- Market Cap
- ACAD 2.8B
- CSAN 2.6B
- IPO Year
- ACAD 2004
- CSAN N/A
- Fundamental
- Price
- ACAD $14.73
- CSAN $4.91
- Analyst Decision
- ACAD Buy
- CSAN Strong Buy
- Analyst Count
- ACAD 16
- CSAN 1
- Target Price
- ACAD $23.93
- CSAN $19.00
- AVG Volume (30 Days)
- ACAD 1.8M
- CSAN 1.4M
- Earning Date
- ACAD 05-07-2025
- CSAN 05-27-2025
- Dividend Yield
- ACAD N/A
- CSAN 7.07%
- EPS Growth
- ACAD N/A
- CSAN N/A
- EPS
- ACAD 1.36
- CSAN N/A
- Revenue
- ACAD $957,797,000.00
- CSAN $7,106,136,253.00
- Revenue This Year
- ACAD $13.07
- CSAN $294.00
- Revenue Next Year
- ACAD $9.88
- CSAN $3.87
- P/E Ratio
- ACAD $10.83
- CSAN N/A
- Revenue Growth
- ACAD 31.85
- CSAN 11.36
- 52 Week Low
- ACAD $13.40
- CSAN $4.31
- 52 Week High
- ACAD $20.68
- CSAN $11.75
- Technical
- Relative Strength Index (RSI)
- ACAD 38.07
- CSAN 47.18
- Support Level
- ACAD $14.34
- CSAN $4.70
- Resistance Level
- ACAD $15.18
- CSAN $4.99
- Average True Range (ATR)
- ACAD 0.80
- CSAN 0.23
- MACD
- ACAD -0.02
- CSAN -0.03
- Stochastic Oscillator
- ACAD 38.22
- CSAN 46.33
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.